The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

As you can see below, at the end of June 2024, Pfizer had US$69.9b of debt, up from US$65.7b a year ago. Click the image for ...

We recently published a list of 10 Best Innovative Stocks that Pay Dividends. In this article, we are going to take a look at ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.

New treatment builds on Pfizer’s migraine portfolio to further meet the needs of people living with this debilitating disease ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Pfizer PFE in the ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...